This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...
Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2…
Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European ...
Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)
Summit Therapeutics' ivonescimab shows a significant PFS improvement over pembrolizumab in NSCLC. Read why I'm bearish on ...
Medscape12d
Ivonescimab: Possible New First-Line Standard in PD-L1-Positive Advanced NSCLC?
VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced ...
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data for the novel, potential ...
Ivonescimab outperforms pembrolizumab in study for first-line treatment of PD-L1-positive advanced NSCLC: Clinical trial
Data from a Phase 3 study has revealed that ivonescimab demonstrates a statistically significant and clinically meaningful ...
Cure Today9d
Frontline Ivonescimab May Further Reduce Progression or Death Risk Versus Keytruda in NSCLC Subset
Some patients with non-small cell lung cancer saw a 49% reduction in the risk of disease progression or death with ...
Ivonescimab: A Rising Star in Oncology with Broad Market Potential
Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Summit Therapeutics (SMMT – Research Report), boosting the price ...
MedPage Today12d
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC
Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Ivonescimab -- a novel first-in-class PD-1/VEGF bispecific antibody -- led to ...
Asia One12d
Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024
Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically ...